Q3 2024 Compugen Ltd Earnings Call Transcript

Nov 12, 2024 / 01:30 PM GMT

Release Date Price: $1.6 (-8.05%)

Transcript

Key Points

Positve

Compugen Ltd (CGEN) reported encouraging data from their studies on COM701, COM902, and pembrolizumab in patients with platinum-resistant ovarian cancer, showing durable responses and good tolerability.
The company received a $30 million milestone payment from Gilead for achieving FDA IND clearance for COM503, indicating strong progress in their partnership.
Compugen Ltd (CGEN) has a strong cash position with approximately $113.2 million, expected to fund operations into 2027, providing financial stability.
The company plans to initiate a new trial in Q2 2025, targeting relapsed platinum-sensitive ovarian cancer patients, which could open new regulatory and commercial opportunities.
Compugen Ltd (CGEN) is eligible for future milestone payments and royalties from AstraZeneca's development of bispecific antibodies, representing a significant potential revenue source.

Negative

The overall response rate in the platinum-resistant ovarian cancer study was only 17%, which may be considered low despite the challenging patient population.
The company faces competition in the ovarian cancer treatment landscape, particularly in maintenance therapy for relapsed platinum-sensitive patients.
There are concerns about the toxicity and side effects of current treatments like Bevacizumab and PARP inhibitors, which Compugen Ltd (CGEN) aims to address with their therapies.
The development of biomarkers for patient selection remains challenging, with no current enrichment strategy for COM701 in the platinum-resistant setting.
The company's future success is heavily reliant on the outcomes of ongoing and planned clinical trials, which carry inherent risks and uncertainties.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CGEN.OQ - Compugen Ltd
Q3 2024 Compugen Ltd Earnings Call
Nov 12, 2024 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's third quarter, 2024 results conference call at this time. All participants are in a listen-only mode, an audio webcast of this call is available in the investors section of Compugen's website www dot CGEN dotcom.

As a reminder, today's call is being recorded. I would now like to introduce Yvonne Naughton, head of Investor Relations and corporate communications. Yvonne. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you yi and thank you all for joining us on the call today. Joining me from

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.